Troglitazone (TRO), an effective thiazolidinedione antidiabetic agent, was reported to produce idiosyncratic hepatotoxic effects in some individuals. In contrast, rosiglitazone (RSG), in the same group of agents, has no significant toxic effects and now is widely used. In this study, human hepatoma (HepG2) cell lines were exposed to various doses of TRO as well as RSG (0, 25, 50, and 75 mM) for 48 h. Cell lysates were separated by two-dimensional electrophoresis, and the gels were stained with coomassie brilliant blue to compare the spot profiles. The greatest protein expression at a MW of 75 kDa and isoelectric point of 5 was specifically increased with TRO treatments of 50 and 75 mM. The spot was identified as a mixture of immunoglobulin heavy chain binding protein (BiP) and, to a lesser extent, protein disulfide isomerase-related protein (PDIrp). Immunoblot analyses showed that the BiP protein was dose-dependently increased by TRO treatment and, to a lower degree, by RSG. These effects were also correlated with the high induction of BiP mRNA by TRO (50 and 75 mM) and the lower induction by RSG. However, both treatments showed no significant effects on PDIrp expression. The toxic effects of TRO in relation to the overexpression of BiP were also demonstrated in HLE cells, another human hepatoma cell line. In HLE cells, the inhibition of BiP expression by small interference RNA rendered cells more susceptible to the toxic effects of TRO. These results suggest that the overexpression of BiP is a defense mechanism of the endoplasmic reticulum in response to TRO-induced toxicity.
Troglitazone (TRO) is one of the thiazolidinedione (TZD) oral antidiabetic agents launched in 1997. This drug has been demonstrated to improve hyperglycemia, hyperinsulinemia, and hypertriglyceridemia, as well as to ameliorate the insulin sensitivity of the target tissues (Fujiwara et al., 1988; Nolan et al., 1994) . Based on its pharmacological advantages and the apparent absence of severe toxic effects, TRO was thought likely to become a promising treatment for type II diabetes mellitus in patients with insulin resistance. However, in the early clinical trials, 1.9% of the patients who received TRO experienced an elevation of serum alanine aminotransferase of more than three times the normal upper limit (Watkins and Whitcomb, 1998) . During the following few years of utilization, TRO has been reported to produce idiosyncratic hepatotoxic effects in some individuals (Gitlin et al., 1998; Neuschwander-Tetri et al., 1998; Shibuya et al., 1998) . Because of the seriousness of the cases, TRO was considered for withdrawal from the market in 2000. The mechanism by which TRO induced toxicity is still not completely understood. Severe hepatotoxic effects have not been observed in any kind of conventional animal models including monkey, which has a similar metabolic profile to human (Rothwell et al., 2002; Watanabe et al., 1999) .
The antidiabetic effects of TZDs occur via the activation of peroxisome proliferator-activated receptor g (PPARg), and the potency correlates to their receptor-binding activities (Lehmann et al., 1995) . There is a less clear association between hepatotoxicity and rosiglitazone (RSG), another TZD agent (Freid et al., 2000; Isley and Oki, 2000; Lebovitz et al., 2002) . Since hepatotoxicity is unique to TRO, it is unlikely to be related to a PPARg class effect.
Even though TRO toxicity has not been observed in in vivo experimental animal studies, a number of in vitro experiments revealed evidence that TRO can cause apoptotic cell death in various hepatic cell types Tirmenstein et al., 2002; Yamamoto et al., 2001) . The degree of lethality also depends on the concentration of the agent and the duration of exposure. Tirmenstein et al. (2002) reported that TRO induces mitochondria permeability transition and decreases in the cellular ATP concentration prior to cell death. Regarding the signaling pathway of apoptosis, reported that TRO but not RSG activates both c-Jun N-terminal protein kinase (JNK) and p38 kinase and causes an increase in proapoptotic proteins such as Bad and Bax, release of cytochrome c, and cleavage of Bid, together with a decrease in antiapoptotic protein, Bcl-2.
In addition to the known mechanisms of apoptotic cell death caused by TRO, we attempted to investigate the involvement of proteins whose up-or down-regulation correlated with the TROinduced toxic effects. Using a proteomic analysis strategy, we analyzed a protein spot on a gel separated by two-dimensional electrophoresis (2-DE) at an approximate MW of 75 kDa and isoelectric point of 5 that increased greatly in correlation with the concentration-dependent exposure to TRO. The spot was identified as a mixture of two chaperones, immunoglobulin heavy chain binding protein (BiP or Grp78) and, to a lesser extent, protein disulfide isomerase-related protein (PDIrp or ERp72). These findings suggest that TRO targets the endoplasmic reticulum (ER) and causes the overexpression of BiP, a prominent chaperone, in response to cytotoxicity. A possible association of BiP in TRO-induced cytotoxicity is also discussed.
MATERIALS AND METHODS
Cell culture condition and treated agents. Human hepatoma cell lines HepG2 and HLE were obtained from the Riken Gene Bank (Tsukuba, Japan, http://www.rtc.riken.go.jp) and the Japanese Collection of Research Biosources (Tokyo, Japan, http://cellbank.nihs.go.jp/cellbank_e.html), respectively. The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM, Nissui Pharmaceutical, Tokyo, Japan) containing 10% fetal bovine serum (FBS, BioWhitaker, Walkersville, MD), 3% glutamine, and 8% sodium bicarbonate at 37 C in a humidified atmosphere with 5% CO 2 . TRO and RSG were kindly provided by Sankyo (Tokyo, Japan). The treated agents were dissolved in dimethyl sulfoxide (DMSO, Wako, Osaka, Japan), in which the final concentration did not exceed 0.1%. In all treatment conditions, the cells were grown in medium containing 5% FBS.
Cytotoxicity assay. To assess the cytotoxicity, a crystal violet assay and an ATP-based luminescent assay were used. Crystal violet assay was used according to Nakagawa et al. (1996) for determining the concentration-and time-dependent toxicity in HepG2 cells. Briefly, a suspension of HepG2 cells (1 3 10 5 cells/well) in the presence of TZDs or 0.1 % DMSO was seeded onto 12-well plates. At the end of treatment, adherent cells were washed three times with phosphate buffered saline (PBS), fixed with 3.7% formaldehyde, and stained with 0.2% crystal violet. The absorbance at 620 nm was measured after extracting the cells with 2% sodium dodecyl sulfate (SDS). Percent cell viabilities were calculated by comparing them to the absorbance of 0.1% DMSO-treated cells.
Cell viabilities based on the quantity of the ATP produced by metabolically active cells were assessed with a CellTiter-Glo Luminescent assay kit (Promega, Madison, WI) according to the manufacturer's protocol. In the concentrationdependent study, a suspension of HepG2 cells (3 3 10 3 cells/well) in the presence of TZDs or 0.1 % DMSO was seeded onto a 96-well plate. At the end of treatment, CellTiter-Glo reagent was added at an equal volume to the cell culture medium present in each well. The generated luminescent signal was monitored on a Wallac 1420 multilabel counter (PerkinElmer, Wellesley, MA).
Preparing cell lysates. HepG2 cells were treated with various doses of TRO or RSG. At the end of the 48-h treatment period, the cells were harvested by treatment with 0.05% trypsin plus 0.02% EDTA. The cells were washed with PBS and lysed with 100-200 ml of lysis solution (8 M urea, 4% CHAPS, 2% Pharmalyte 3-10) containing protease inhibitors (1 mM DTT, 0.5 mM APMSF, 2 mg/ml aprotinin, 2 mg/ml pepstatin, and 2 mg/ml leupeptin). The cell suspension was centrifuged at 12,000 rpm for 1 h to remove cell debris. The supernatant was collected, and the protein concentration was measured using a Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Hercules, CA). The cell lysates were stored at À80 C until the time of analysis.
2-Dimensional electrophoresis (2-DE).
The devices and chemicals used in 2-DE were purchased from Amersham Biosciences, Buckinghamshire, UK. For the first dimension, 500 mg of protein of the cell lysates was mixed with Destreak Rehydration Solution containing immobilized pH gradient (IPG) buffer of pH 4-7 and applied onto IPG gel strips. The samples were rehydrated at 20 C for 14 h and subsequently separated at 17,500 V-h using an Ettan IPGphor Isoelectric Focusing System. The second dimensional electrophoresis was run on 10% acrylamide gel at 10 C for 4 h. The separated proteins on 2-DE were visualized by coomassie brilliant blue (CBB) staining.
Protein identification. The amino acid sequence analyses from the CBBstained two-dimensional (2-D) gels were performed at Hitachi Science Systems, Ltd., Japan. The protein spot of interest was excised from the CBB-stained gel of the sample treatment with 75 mM TRO. After in-gel digestion with trypsin, the peptides were reduced and carbamidomethylated. The peptide mass mapping was performed on an ESI-TRAP and analyzed by LC/MS/MS. The matched peptides were searched using MASCOT (http://www.matrixscience.co.uk) based on the NCBInr database.
Western blot analysis. The HepG2 cell lysates (50 mg for BiP, and 25 mg proteins for PDIrp and PDI proteins) were separated on 10% SDSpolyacrylamide gels and transferred onto PVDF membrane (Immobilon-P, Millipore, Billerica, MA). The specific proteins were detected by mouse anti-KDEL monoclonal antibody (SPA-827, Stressgen, San Diego, CA) for BiP, rabbit antiERp72 polyclonal antibody (SPA-720, Stressgen) for PDIrp, and rabbit anti-PDI polyclonal antibody (SPA-890, Stressgen) for PDI proteins at dilutions of 1:200, 1:2000, and 1:2000, respectively. The protein bands were developed by biotinylated second antibody-peroxidase reaction. The quantitative analysis of protein expression was performed using a densitometer GS-700 (Bio-Rad Laboratories).
Reverse transcription and real-time PCR. Human hepatoma cells were treated with or without TZDs. At the end of the incubation periods, the cells were washed with PBS, and the total RNA was prepared using Isogen 1 (Nippon Gene, Tokyo, Japan) according to the manufacturer's instructions. Reverse transcription (RT) reactions were carried out by incubating 2 mg of total RNA with random primer (Takara, Tokyo, Japan) and Moloney-Murine Leukemia Virus Reverse transcriptase (M-MLV-RT) RNaseH Minus (Toyobo, Tokyo, Japan) at 37 C for 1 h. Subsequently, the steady state of the mRNA levels was quantified by fluorescence-based real-time PCR. Oligonucleotide sense and antisense primers of human-BiP (5 0 -TGCTTGATG-TATGTCCCCTTA-3 0 and 5 0 -CCTTGTCTTCAGCTGTCACT-3 0 ) and PDIrp (5 0 -AATACCAGGATGCCGCTAAC-3 0 and 5 0 -GCAAAGGTGTACTCAGG-GAA-3 0 ) as well as GAPDH (5 0 -CCAGGGCTGCTTTTAACTC-3 0 and 5 0 -GCTCCCCCCTGCAAATGA-3 0 ) were used. The reaction mixture for real-time PCR containing 1 ml of RT product, Ex Taq R-PCR Version (Takara, Japan), SYBR 1 Green I (Molecular Probes, Eugene, OR), and the specific sense and antisense primers were subjected to a Smart Cycler 1 System (Cepheid, Sunnyvale, CA). After a holding step at 95 C for 30 s, the thermal cycling was repeated for 45 cycles of 94 C for 4 s and 64 C for 20 s, followed by melting from 60 C to 95 C at 0.2 C/s. The standard curve for the relative quantification was created by serially diluted GAPDH concentrations plotted against the threshold cycle number from the real-time PCR reaction. The BiP and PDIrp expressions were evaluated, and the relative values were normalized with the GAPDH values from the same DNA samples.
siRNA generation. Small interference RNA (siRNA) for BiP (Accession AF188611) and human lamin A (Accession X03444) mRNA target sequences were created and checked by the species-appropriate genome database (http:// www.ncbi.nlm.nih.gov/BLAST/) to avoid target sequences homologous to other known coding sequences. The sense and antisense primers for BiP were 5 0 -CAACTGTTACAATCAAGGTC-3 0 and 5 0 -CTGTATCCTCTTCAC-CAGTT-3 0 , and for lamin A were 5 0 -AAAGCGCGCAATACCAAGAA-3 0 and 5 0 -CCTCACTGTAGATGTTCTTC-3 0 , designed with the T7 RNA polymerase promoter sequences (CTAATACGACTCACTATAGGGAGG) at the 5 0 -end of each primer. The target genes were amplified by PCR and purified by ethanol precipitation. dsRNAs were generated using a T7 RiboMAX TM Express Large Scale RNA Production System Kit (Promega) according to the manufacturer's protocol. The dsRNAs were then diced into 20-23 bp of siRNAs by incubating them with recombinant dicer enzyme (GTS, San Diego, CA) for 18 h. The obtained siRNAs were further subjected to two purification steps, removal of the salts with a Sephadex G25 column (Amersham Biosciences) and the undigested dsRNA by centrifugation with a Microcon YM-100 (Millipore). The purified siRNA duplexes were stored at À80 C until analysis. Transfection of siRNA. In order to knockdown target genes at the transcriptional level, siRNA was transfected into the cells. Because of the difficulty to transfect siRNA into HepG2 cells, HLE cells, another human hepatoma cell line that demonstrates similar BiP expression profiles to HepG2 cells (data not shown), were used in this experiment. Briefly, HLE cells were seeded onto 6-well plates (8 3 10 4 cells/well) or 96-well plates (3 3 10 3 cells/well) and incubated for 24 h before transfection. At approximately 30-50% confluency, the cells were transfected with siRNA using Oligofectamine (Invitrogen, Carlsbad, CA) for 24 h. The cells were treated with TZDs or DMSO at the concentrations indicated for 24 h before analysis.
Statistical analysis. Data were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's post hoc test using Instat version 2.0 software; p 5 0.05 was considered significant.
RESULTS

Troglitazone-Induced HepG2 Cell Toxicity
To investigate the toxic effects of TRO, crystal violet assay was used to determine the concentration-and time-dependent cytotoxicity. ATP-based luminescent assay was used for the sensitive detection of a small amount of viable cells. In the concentration-dependent experiment, HepG2 cells were exposed to various concentrations of TRO of 0 (0.1% DMSO), 5, 10, 25, 50, 75, and 100 mM as well as the same concentrations of RSG as negative controls. After 48 h of treatment, !25 mM TRO significantly reduced the cell viability with an approximate IC 50 of 40 mM, whereas RSG showed no significant toxic effects (Fig. 1A) . TRO also showed a time-dependent cytotoxicity in HepG2 cells from 24 h to 60 h of exposure ( p 5 0.01) compared to the DMSO treatment (Fig. 1B) . The concentrationdependent cytotoxicity of TRO (Fig. 1A) was comparable to the reduction of ATP produced by viable metabolically active cells as detected by the ATP-based luminescent assay (Fig. 1C) .
Proteomic Analysis for Troglitazone-Induced Hepatotoxicity
The different toxic effects of TRO and RSG were investigated by proteomic analysis to determine the differences in the protein expression profiles. HepG2 cells were treated with or without various doses of TRO or RSG for 48 h. Cell lysates were prepared and subjected to 2-DE analysis. The gels were then stained with CBB. A number of spots were up-and down-regulated by the treatments. We focused on the spot showing a large amount of protein expression, which showed dose-dependent and TROspecific changes, at an approximate MW of 75 kDa and isoelectric point of 5. The expression was increased by treatment with 50 and 75 mM of TRO ( Fig. 2A) . At the same position, RSGtreated cells demonstrated no difference compared to the DMSO-treated control (Fig. 2B) . The spot was excised, subjected to amino acid sequence analysis and identified as a mixture of immunoglobulin binding protein (BiP) (Fig. 3A) and, to a lesser extent, protein disulfide isomerase-related protein (PDIrp or ERp72) (Fig. 3B) . Notably, BiP was prominent in this finding, as indicated by the higher total score (1341) compared to PDIrp (294), and these proteins had MWs and calculated isoelectric point values near the position that appeared on the 2-D gels.
Changes of Chaperone Proteins and mRNAs by TZDs Exposure
HepG2 cells were incubated in the presence of various concentrations of TRO or RSG or 0.1% DMSO (control) for 48 h. The cell lysates were confirmed for the expressions of BiP and PDIrp proteins by Western blot analyses with specific antibodies. In Figure 4A , BiP protein detected by anti-KDEL antibody was markedly increased in intensity by increasing the TRO concentration and was about 5-fold at 100 mM. The same phenomenon was also demonstrated with RSG treatment but with a relatively smaller increase, even at 100 mM (about 2.5-fold). The expression of PDIrp as detected by anti-ERp72 antibody showed no significant difference among the treatments (Fig. 4B) . We also investigated the expression of PDI protein and there was no significant difference (Fig. 4C) . To further investigate the control of BiP and PDIrp expressions at the transcription level, the mRNAs were determined by real-time PCR. Comparing the results from the Western blot analyses, BiP mRNA expression by TRO treatment was also dose-dependently induced, with the highest level at 75 mM (about 11-fold) (Fig. 5A) . However, at 100 mM of TRO, BiP mRNA was comparable to the control because of cell toxicity. RSG-treated cells showed a small tendency to increase, with significance at the higher doses of 75 and 100 mM (Fig. 5A ). Although PDIrp protein was equally expressed in the presence of all treatments, mRNA expression in response to TRO and RSG treatment showed the induction at the doses of 75 and 100 mM (Fig. 5B) .
Inhibition of BiP Expression by siRNA
All the above results demonstrated the obvious effects of TRO compared to RSG on BiP overexpression. To clarify these 
FIG. 3.
Amino acid sequences analyzed from the 2-D gel spot. The protein spot of interest was excised from the CBB stained gel of the sample treated with 75 mM TRO and subjected to amino acid sequence analyses as described in Materials and Methods. The 'Bold Underlined' sequences denote peptides which matched with both BiP (A) and PDIrp (B).
FIG. 4.
Western blot analyses. HepG2 cells were incubated with 0.1% DMSO (control) or the indicated concentrations of TRO or RSG for 48 h. The cell lysates were subjected to Western blot analysis with mouse anti-KDEL (A), rabbit anti-ERp72 (B), and rabbit anti-PDI (C) antibodies for BiP, PDIrp, and PDI proteins, respectively. Two additional studies yielded equivalent results. The expressions of BiP, PDIrp, and PDI proteins were measured using a densitometer. The data represent the mean 6 SD of three independent experiments. **p 5 0.01 compared with the control.
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effects, an RNA interference technique was carried out for knockdown BiP expression. Because of the difficulty in transfecting siRNA into HepG2 cells, human hepatoma HLE cells were used instead. In our previous report, TRO possessed toxic effects on HLE cells as well as HepG2 cells, but with somewhat higher sensitivity (Yamamoto et al., 2001) . The BiP mRNA expression in HLE cells treated with TRO and RSG showed a similar pattern to that in HepG2 cells (data not shown). Compared to mock-transfected cells, BiP expression with DMSO treatment (control) was diminished by 50 and 100 nM of siRNA by about 30 and 17%, respectively. Furthermore, when additionally treated with 75 mM of TRO, the BiP mRNA was dramatically suppressed from 16-fold to 1.7-and 1.6-fold, respectively (Fig. 6A) . Similarly, in siRNA-transfected cells treated with 100 mM of RSG, the BiP mRNA was suppressed from 2.5-fold to 0.6-and 1.0-fold, respectively (Fig. 6A) . The BiP protein expression was also investigated in HLE cells after transfection with 50 nM BiP siRNA and subsequent treatment with TRO and RSG at concentrations of 75 and 100 mM, respectively. Figure 6B shows the inhibition of BiP protein production compared to the mock-transfected control under both control (DMSO) and treatment conditions assessed by Western blot analyses.
Cell Viability Changes by Troglitazone Treatment in BiP-Suppressed Cells
BiP inhibition by siRNA was clearly demonstrated, especially in the presence of TRO and RSG, to be superior to that of the mock-transfected control. Accordingly, HLE cells were then investigated in terms of the phenotypic changes. The ATP-based luminescent assay was used to measure the cell viability. In the DMSO-treated control there was a dosedependent decrease in cell viability by BiP siRNA transfection (Fig. 7A) , whereas there were no significant changes by lamin A siRNA, a negative control of siRNA transfection (Fig. 7B) . Interestingly, 50 mM TRO treatments caused a significant decrease in cell viability with 10 nM of BiP siRNA ( p 5 0.05) and a marked decreased ( p 5 0.01) at the high concentration of 25 to 100 nM of BiP siRNA compared to the DMSO-treated control (Fig.7A) . The 75 mM TRO treatment demonstrated significant toxic effects ( p 5 0.01) in all BiP siRNA-transfected concentrations including the mock-transfected cells (transfected control). RSG at the concentration of 75 and 100 mM showed comparable results with the DMSO with both BiP siRNA and lamin A siRNA transfection (Figs. 7A and 7B ).
DISCUSSION
The toxicological potential of TRO compared to that of another TZD agent, RSG, was investigated in a human hepatoma cell line, HepG2. In this study, TRO treatment showed concentration-dependent cytotoxicity with an approximate IC 50 of 40 mM, whereas only a slight decrease in cell viability was found with RSG treatment (Fig. 1A) . These results were consistent with the previous reports, which additionally revealed that the lethal effects are exemplified by apoptosis Yamamoto et al., 2001) . In our findings, the toxic effects of TRO in HepG2 cells were also exhibited in a time-dependent manner (Fig. 1B) and were significantly observed from 24 h of exposure. Although RSG showed a significant decrease in cell viability from 48 h to 60 h ( p 5 0.05), cell viabilities were more than 80% of the control ( Fig. 1B) . The crystal violet assay in our protocol could not detect the time-dependent cytotoxicity, because the cells were not adherent before 24 h after seeding. We also confirmed with the trypan blue exclusion assay in a time-course experiment from 4 to 60 h. The percent cell viabilities were comparable to those detected with crystal violet, and significant lethal effects were observed from 12 to 60 h by 50 mM TRO exposure (data not shown). TRO has been reported to be metabolized to three main metabolites: sulfate-conjugated, glucuronide-conjugated, and quinone-type (TRO quinone) metabolites (Izumi et al., 1997a,b; Kawai et al., 1998) . TRO, but not RSG, contains a 6-hydroxy-5,7,8-trimethylchromane moiety, which undergoes metabolic activation by hepatic cytochrome P450 enzymes, CYP2C8 and CYP 3A4, to generate TRO quinone (Tettey et al., 2001; Yamazaki et al., 1999) . Based on the general involvement of quinones in cytotoxicity, TRO quinone has been reported to have a possible association with TRO-induced hepatotoxicity (Neuschwander-Tetri et al., 1998) . Previously, we 
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found a major epoxide of the quinone metabolite of TRO in HepG2 cells (Yamamoto et al., 2002) . However, the toxicity possessed by either TRO quinone or the epoxide of TRO quinone is relatively lower than that of the parent compound (Tettey et al., 2001; Yamamoto et al., 2001 Yamamoto et al., , 2002 . Thus, the hepatotoxic effects were more likely due to TRO or other unknown metabolites.
Since the remarkable cytotoxicity of TRO has been established, we used 2-DE to investigate the protein expression profiles of HepG2 cells treated with various concentrations of TRO or RSG. On 2-D gels, more than ten different spots according to the treatments were revealed (small part shown in Fig. 2) . We focused on a spot of interest at an approximate MW of 75 kDa and isoelectric point of 5, which showed distinct dosedependency and TRO-specific changes with the greatest expression. The protein spot was highly matched with BiP and also, to a lesser extent, PDIrp (Fig. 3) . These proteins are recognized as chaperone proteins that reside in the ER (Gething and Sambrook, 1992) .
BiP, known as a 78 kDa glucose-regulated protein (Grp78), is related to the highly conserved 70 kDa heat shock protein (hsp70) family (Munro and Pelham, 1986) . Apart from its response to heat, BiP is also the best-characterized chaperone and is abundantly and constitutively expressed in the ER of all eukaryotic cells (Gething and Sambrook, 1992; Haas, 1994) . This protein is responsible for normal cellular functions such as assisting protein folding, assembly, and disassembly for maintenance, as well as the degradation of untenable proteins. BiP production can be induced by various perturbations of ER functions such as the expression of mutant proteins or protein subunits, reductive stress, ER Ca 21 depletion, and the inhibition of asparagine (N)-linked glycosylation (Gething and Sambrook, 1992; Haas, 1994; Kaufman, 1999 , Lee, 2001 ). In our study, TRO treatment elicited a dose-dependent overexpression of BiP protein, as confirmed by Western blot analyses (Fig. 4A) . BiP mRNA was also induced by treatment with 50 and 75 mM of TRO (Fig. 5A) . At 100 mM TRO treatment, which resulted in about 15% cell viability, the highest induction of BiP protein was observed, but not the mRNA. Gülow et al. (2002) reported that under ER stress conditions, BiP expression is tightly controlled post-transcriptionally, allowing the cells to produce more proteins which are independent from the transcription level. As shown in Figure 6B , we confirmed that, with the inhibition of BiP mRNA expression before TRO or RSG treatment, the induction of BiP protein could not be achieved. Thus, the effects of 100 mM TRO treatment could be in part explained by the high translation efficiency of BiP protein in HepG2 cells. In our observation, RSG treated-HepG2 cells also induced BiP expression but at a low level, which would account for its lower toxicity compared to TRO.
Protein disulfide isomerase-related protein (herein referred to as PDIrp), or 72 kDa endoplasmic reticulum protein (ERp72), is also a resident chaperone in the ER which shares amino acid sequences with ERp59 (PDI) and holds three copies of the thioredoxin active unit as well as PDI activity in vitro (Gething and Sambrook, 1992; Mazzarella et al., 1990) . In normal cells, PDIrp is expressed constitutively at low levels and is induced by the same treatments that affect BiP expression (Huang et al., 1989) . We found PDIrp close to the BiP spot. However, unlike BiP, PDIrp protein was expressed equally in all treatments (Fig.  4B) . Given the similar characteristics between PDIrp and PDI (Mazzarella et al., 1990) , we also investigated the PDI protein level in the same set of treated samples using its specific antibody. Indeed, the PDI protein expression showed comparable results (Fig. 4C) to PDIrp. Although a small induction of PDIrp mRNA was observed at the high doses of 75 and 100 mM, neither treatment lead to the overproduction of the protein. These present data suggest that the damage caused by TRO treatment was unlikely related to the increased PDI proficiency.
In order to confirm the prominent regulation of BiP by TROinduced cytotoxicity, the RNA interference method was applied to HLE, another human hepatoma cell line. In the condition of siRNA transfection with TRO treatment, BiP expression was suppressed by about 90% compared to the corresponding mocktransfected cells (Fig.6A ). This finding was reflected by the phenotypic change in cell viability. TRO caused changes in the permeability and structure of mitochondria as well as a depletion of ATP, which were correlated with the decrease of cell viability (Tirmenstein et al., 2002) . With a small amount of cells, the luminescent assay was considered to be sufficiently sensitive to detect the relative ATP (Fig. 1C) and showed parallel results with the cell viability in Figure 1A . Thus, to observe the phenotypic changes caused by the TRO-induced suppression of BiP, ATP produced by metabolically active cells was used as a biomarker in this study. Comparing the results in Figures 7A and 7B, we found that the inhibition of BiP appeared to promote cell death even in the absence of TRO. This supports the crucial function of BiP in normal cellular processes (Gething and Sambrook, 1992; Haas, 1994; Kaufman, 1999) . Doses of 50 and 75 mM TRO as well as 75 and 100 mM RSG, which caused the high levels of BiP mRNA expression, were used. Interestingly, in the presence of 50 mM TRO, the inhibition of BiP expression rendered cells more susceptible to the lethality, as demonstrated by a gradual increase in significant cell toxicity along with the increase in the concentration of BiP siRNA (Fig. 7A) . Supporting this finding, a related study reported that inhibition of BiP synthesis sensitizes cells to oxidative stress (Liu et al., 1998) . These phenotypic changes in cell viability suggested the crucial role of BiP overexpression in the effects of TRO exposure.
It is well known that ER is a major cellular storage site of Ca 21 in the cell, and ER chaperones also play important roles in Ca 21 accumulation and release. Both BiP and PDIrp are Ca 21 -binding proteins (Lee, 2001) . Any disturbance in the ER homeostasis causes a release of Ca 21 , which in turn blocks ER protein processing, resulting in the accumulation of incompletely folded proteins, and activates the transcription of ER chaperone genes including BiP (Liu et al., 1998; Lodish and Kong, 1990) . In previous reports, TRO but not RSG exhibited antiproliferative effects on cultured cells via a depletion of Ca 21 from the storage site that results in the inhibition of translation initiation (Fan et al., 2004; Palakurthi et al., 2001) . Together with our results, it might be postulated that TRO acts as a chemical signal that causes the release of Ca 21 from the ER, and that BiP expression is one of the cellular responses induced by TRO toxicity. In addition, the effects of TRO on the activation of JNK pathway , disturbance of mitochondria function, and depletion of ATP (Tirmenstein et al., 2002) may also converge in the ER stress response (Breckenridge et al., 2003) .
In conclusion, the possibility was raised in the present study that the ER is one of the targets involved in TRO hepatotoxicity. TRO may serve as a stress signal to the ER, which in turn causes the overproduction of BiP in response to cytotoxicity. Supporting this view, the inhibition of BiP at the post-transcriptional level sensitized the cells to lethality.
